Recombinant　virus-based　transgene　therapy　has　shown　promising　results　in　solid　tumors.　Oncolytic　virotherapy　is　a　research　hotspot　because　of　its　additional　immunostimulatory　effects.　However,　metastatic　malignancies　require　systemic　virotherapy,　which　necessitates　the　use　of　safe　and　effective　vehicles　for　drug　delivery.　Mesenchymal　stem　cells　(MSCs)　are　good　carriers　because　of　their　tumor　tropic　and　immune-evasive　capabilities.　We　collated　published　results　from　pre-clinical　and　clinical　trials　to　support　the　use　of　MSCs　as　Trojan　horses　for　the　systemic　administration　of　recombinant　viruses,　with　a　focus　on　glioblastoma.　The　generation　of　modified　MSCs　harboring　recombinant　viruses　could　expedite　bench-to-bedside　transformation.